Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Non-Current Assets (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Other Non-Current Assets for 12 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets rose 1368.57% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Sep 2025, up 1368.57%, and an annual FY2024 reading of $1.0 million, up 1137.35% over the prior year.
  • Other Non-Current Assets was $1.0 million for Q3 2025 at CytomX Therapeutics, up from $56000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.0 million in Q1 2025 and bottomed at $27000.0 in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $710368.4, with a median of $917000.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Assets crashed 97.06% in 2022, then skyrocketed 1368.57% in 2025.
  • Year by year, Other Non-Current Assets stood at $917000.0 in 2021, then plummeted by 97.06% to $27000.0 in 2022, then surged by 207.41% to $83000.0 in 2023, then surged by 1137.35% to $1.0 million in 2024, then rose by 0.1% to $1.0 million in 2025.
  • Business Quant data shows Other Non-Current Assets for CTMX at $1.0 million in Q3 2025, $56000.0 in Q2 2025, and $1.0 million in Q1 2025.